JP2020529847A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529847A5
JP2020529847A5 JP2020505464A JP2020505464A JP2020529847A5 JP 2020529847 A5 JP2020529847 A5 JP 2020529847A5 JP 2020505464 A JP2020505464 A JP 2020505464A JP 2020505464 A JP2020505464 A JP 2020505464A JP 2020529847 A5 JP2020529847 A5 JP 2020529847A5
Authority
JP
Japan
Prior art keywords
cancer
immune cells
types
cells
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529847A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/044740 external-priority patent/WO2019028098A1/en
Publication of JP2020529847A publication Critical patent/JP2020529847A/ja
Publication of JP2020529847A5 publication Critical patent/JP2020529847A5/ja
Pending legal-status Critical Current

Links

JP2020505464A 2017-08-03 2018-08-01 がんの処置のための方法および組成物 Pending JP2020529847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762540901P 2017-08-03 2017-08-03
US62/540,901 2017-08-03
PCT/US2018/044740 WO2019028098A1 (en) 2017-08-03 2018-08-01 METHODS AND COMPOSITIONS FOR TREATING CANCER

Publications (2)

Publication Number Publication Date
JP2020529847A JP2020529847A (ja) 2020-10-15
JP2020529847A5 true JP2020529847A5 (cg-RX-API-DMAC7.html) 2021-09-09

Family

ID=65234162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505464A Pending JP2020529847A (ja) 2017-08-03 2018-08-01 がんの処置のための方法および組成物

Country Status (10)

Country Link
US (1) US20200155600A1 (cg-RX-API-DMAC7.html)
EP (1) EP3661953A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020529847A (cg-RX-API-DMAC7.html)
KR (1) KR20200036874A (cg-RX-API-DMAC7.html)
CN (1) CN111094328A (cg-RX-API-DMAC7.html)
AU (1) AU2018308982A1 (cg-RX-API-DMAC7.html)
CA (1) CA3071448A1 (cg-RX-API-DMAC7.html)
IL (1) IL272147A (cg-RX-API-DMAC7.html)
SG (1) SG11202000724XA (cg-RX-API-DMAC7.html)
WO (1) WO2019028098A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3952909A4 (en) * 2019-04-08 2023-06-07 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS
SG11202112529WA (en) * 2019-05-14 2021-12-30 Taiga Biotechnologies Inc Compositions and methods for treating t cell exhaustion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358739B1 (en) * 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US20040241140A1 (en) * 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same
AU2003216288B2 (en) * 2002-02-13 2009-09-24 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US20060222657A1 (en) * 2003-06-20 2006-10-05 Dowdy Steven F Polypeptide transduction and fusogenic peptides
US8883507B2 (en) * 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
US8784825B2 (en) * 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
JP6285930B2 (ja) * 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ,インク. 造血コンパートメントの再構築及び自家再構築の増進
US9365825B2 (en) * 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
EP3461491B1 (en) * 2013-04-18 2024-11-13 TILT Biotherapeutics Oy Enhanced adoptive cell therapy
US10149898B2 (en) * 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
EP4026554A1 (en) * 2017-08-03 2022-07-13 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Similar Documents

Publication Publication Date Title
ES3037919T3 (en) Mage a4 t cell receptors
TWI822726B (zh) Nyeso t細胞受體
US20220098300A1 (en) Anti trbc1 antigen binding domains
Kiesgen et al. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies
JP2021058197A5 (cg-RX-API-DMAC7.html)
JP2024074801A5 (cg-RX-API-DMAC7.html)
CN118546959A (zh) Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
JP7227630B2 (ja) Y182t突然変異を有するt細胞-抗原カプラおよびその方法ならびに使用
JP2020517259A5 (cg-RX-API-DMAC7.html)
JP2022512541A5 (cg-RX-API-DMAC7.html)
TW201619377A (zh) Car表現載體及car表現t細胞
JP2019534246A5 (cg-RX-API-DMAC7.html)
WO2021048724A1 (en) Combined expression of a chimeric cd3 fusion protein and an anti-cd3-based bispecific t cell activating element
Franks et al. New anticancer immunotherapies
IL301995A (en) Cells comprising t cell-antigen couplers and uses thereof
JP2021512637A5 (cg-RX-API-DMAC7.html)
CN110114057A (zh) Tlr9激动剂对癌症治疗的免疫调节作用
JP2021525068A5 (cg-RX-API-DMAC7.html)
Long et al. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
CN115023237A (zh) 癌症或肿瘤的治疗方法
JP2022547809A5 (cg-RX-API-DMAC7.html)
WO2022033483A1 (zh) 多功能的免疫效应细胞及其应用
EP4367141A1 (en) Gpc3 t cell-antigen couplers and uses thereof
US12479903B2 (en) CD5 specific T cell receptor cell or gene therapy
JP2022503621A5 (cg-RX-API-DMAC7.html)